Biological E starts Phase I/II trial, Bharat Bio to begin Phase III trials for COVID-19 vaccine candidates

Both the vaccines candidates will be administered in two doses via intramuscular injections 28 days apart.

tech2 News Staff November 19, 2020 09:42:04 IST
Biological E starts Phase I/II trial, Bharat Bio to begin Phase III trials for COVID-19 vaccine candidates

Biological E. Ltd will start Phase I and II human trials while Bharat Biotech will begin Phase III.

Hyderabad-based Biological E Ltd has begun an adaptive Phase I and II human trial for its COVID-19 vaccine candidate. The firm has already sought approvals from Drugs Controller General of India (DGCI) and expects to get the results back by February, next year.

It is being developed along with Baylor College of Medicine (BCM ventures) in Houston, Texas, and Dynavax Technologies Corp.

According to the press release, the trial will test two doses of the vaccine in around 360 volunteers who are aged between 18 to 65 years. It will be administered via intramuscular injection 28 days apart. Intramuscular injection is a technique used to deliver the vaccine deep into the muscles, allowing it to be absorbed into the bloodstream quickly.

The vaccine will include an antigen form BCM Ventures and Dynavax’s advanced adjuvant CpG 1018. An adjuvant is a substance that increases the potency and regulates the immune responses to an antigen to improve them.

Bharat Biotech's COVAXIN

On the other hand, Bharat Biotech has also announced that it will soon begin Phase III of its COVID-19 vaccine candidate - COVAXIN. It will involve 26,000 volunteers across India and will be conducted in partnership with the Indian Council of Medical Research (ICMR).

The vaccine is being developed by Bharat Biotech in partnership with ICMR and the National Institute of Virology (NIV).

According to a press release, COVAXIN has already been tested out in Phase I and II trials with 1000 subjects and has shown promising results.

This trial will be conducted in 22 centres across the country and participants will receive two intramuscular injections approximately 28 days apart, a press release stated. However, one group will be injected with a placebo and the other will be injected with the actual vaccine.

According to clinical trial norms, each trial centre has its own ethics committee which monitors the trials conducted at each respective centre and overlooks whether it is meeting the ethics and the study protocol. According to data from the government’s clinical trial registry, eight centres have received their approvals from their respective ethics committees for the clinical trials.

LiveMint reported that Bharat Biotech executive director Sai Prasad said that the company plans to launch the vaccine by June next year unless the government decides to give them emergency use authorisation before that.

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

With China ban some frozen foods, can SARS-CoV-2 survive and be transmitted from packaging?
science

With China ban some frozen foods, can SARS-CoV-2 survive and be transmitted from packaging?

A positive test “doesn’t indicate infectious virus, just that some signal from the virus is present on that surface,” said Andrew Pekosz of Johns Hopkins University’.

Alcohol-free hand sanitisers with benzalkonium chloride efficient at preventing SARS-CoV-2 virus transmission: Study
Health

Alcohol-free hand sanitisers with benzalkonium chloride efficient at preventing SARS-CoV-2 virus transmission: Study

BYU researchers set out to evaluate the efficacy of four commercially available quaternary ammonium compounds (QACs) including benzalkonium chloride against the SARS-CoV-2 virus

Bharat Biotech underplays adverse event in Covaxin Phase 1 trial as start date for Phase 3 nears
India

Bharat Biotech underplays adverse event in Covaxin Phase 1 trial as start date for Phase 3 nears

The volunteer, who had no comorbidities, developed viral pneumonitis after being given a dose of the COVAXIN shot.